Tonix Pharma Files 8-K: Director Changes & Officer Compensation
Ticker: TNXP · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1430306
Sentiment: neutral
Topics: governance, officer-compensation, director-changes
Related Tickers: TNXP
TL;DR
Tonix Pharma 8-K: Board shakeup and exec pay details filed.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on February 27, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements for officers. The filing also includes financial statements and exhibits, with the report being filed as of March 4, 2025.
Why It Matters
This filing provides insight into the company's governance and executive compensation structure, which can impact investor confidence and future strategic decisions.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can signal internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- February 27, 2025 (date) — Earliest event reported
- March 4, 2025 (date) — Filing date
- Nevada (jurisdiction) — State of Incorporation
- 26 Main Street, Chatham, New Jersey, 07928 (address) — Principal executive address
FAQ
What specific changes were made regarding directors and officers?
The 8-K reports on the departure of directors, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing was on February 27, 2025.
What is the company's state of incorporation?
Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.
What is the principal executive address of Tonix Pharmaceuticals?
The principal executive address is 26 Main Street, Suite 101, Chatham, New Jersey, 07928.
What other items are included in this 8-K filing besides director and officer information?
The filing also includes Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).